Source:http://linkedlifedata.com/resource/pubmed/id/18292535
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-2-22
|
pubmed:abstractText |
CD4+ T cells enhance tumor destruction by CD8+ T cells. One benefit that underlies CD4+ T cell help is enhanced clonal expansion of newly activated CD8+ cells. In addition, tumor-specific CD4+ help is also associated with the accumulation of greater numbers of CD8+ T cells within the tumor. Whether this too is attributable to the effects of help delivered to the CD8+ cells during priming within secondary lymphoid tissues, or alternatively is due to the action of CD4+ cells within the tumor environment has not been examined. In this study, we have evaluated separately the benefits of CD4+ T cell help accrued during priming of tumor-specific CD8+ T cells with a vaccine, as opposed to the benefits delivered by the presence of cognate CD4+ cells within the tumor. The presence of CD4+ T cell help during priming increased clonal expansion of tumor-specific CD8+ T cells in secondary lymphoid tissue; however, CD8+ T cells that have low avidity for tumor Ag were inefficient in tumor invasion. CD4+ T cells that recognized tumor Ag were required to facilitate accumulation of CD8+ T cells within the tumor and enhance tumor lysis during the acute phase of the response. These experiments highlight the ability of tumor-specific CD4+ T cells to render the tumor microenvironment receptive for CD8+ T cell immunotherapy, by facilitating the accumulation of all activated CD8+ T cells, including low-avidity tumor-specific and noncognate cells.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
180
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3122-31
|
pubmed:dateRevised |
2011-1-28
|
pubmed:meshHeading |
pubmed-meshheading:18292535-Adoptive Transfer,
pubmed-meshheading:18292535-Animals,
pubmed-meshheading:18292535-CD4-Positive T-Lymphocytes,
pubmed-meshheading:18292535-CD8-Positive T-Lymphocytes,
pubmed-meshheading:18292535-Cancer Vaccines,
pubmed-meshheading:18292535-Cell Movement,
pubmed-meshheading:18292535-Clone Cells,
pubmed-meshheading:18292535-Epitopes, T-Lymphocyte,
pubmed-meshheading:18292535-Insulinoma,
pubmed-meshheading:18292535-Lymphocyte Activation,
pubmed-meshheading:18292535-Mice,
pubmed-meshheading:18292535-Mice, Transgenic,
pubmed-meshheading:18292535-Pancreatic Neoplasms,
pubmed-meshheading:18292535-Rats
|
pubmed:year |
2008
|
pubmed:articleTitle |
Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells.
|
pubmed:affiliation |
Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|